The arithmetic of bacterial resistance is unforgiving. In 2019 alone, drug-resistant infections contributed to roughly 1.27 million deaths worldwide—a figure that rivals malaria and exceeds HIV/AIDS mortality, according to a landmark Lancet study published three years later. Yet the market for new antibiotics remains, to put it mildly, inhospitable. Drugs that work get shelved because hospitals ration them to preserve efficacy. Developers go bankrupt even after FDA approval. The incentives, as industry veterans put it, are upside down.
Which makes Telum Therapeutics' recent €18 million Series A round all the more notable—not for its size, which is modest by biotech standards, but for what it represents. The Spain-based startup announced the financing in July 2026, led by the AMR Action Fund, the industry's largest venture vehicle focused exclusively on fighting antimicrobial resistance. The capital will push Telum's lead candidate, an engineered phage enzyme targeting one of the hospital world's most feared superbugs, into human trials.
It's a milestone that arrives amid cautious optimism—or perhaps stubborn persistence—that the antibiotic market might finally be fixable.
When Viruses Become Weapons
Telum's technology hinges on a biological irony: bacteriophages, the viruses that prey on bacteria, have spent billions of years perfecting the art of killing their hosts. The company's scientists mine these viral assassins for lytic enzymes—proteins that slice through bacterial cell walls with surgical precision—then use synthetic biology and generative AI to optimize them for therapeutic use.
The immediate target is Acinetobacter baumannii, a carbapenem-resistant pathogen that haunts intensive care units and ventilator wards. The World Health Organization ranks carbapenem-resistant A. baumannii in its "Critical" priority tier, the most urgent category for new drug development. Infections often emerge in patients already gravely ill, complicating treatment and driving mortality rates that can exceed 50% in some settings.
"Acinetobacter baumannii represents one of the most formidable threats in the fight against antimicrobial resistance," Henry Skinner, CEO of the AMR Action Fund, said in announcing the investment. It's a threat the FDA acknowledged when it approved XACDURO, a sulbactam-based combination, for A. baumannii lung infections in May 2023—establishing a recent, if narrow, treatment benchmark.
Telum's approach differs. Rather than traditional small molecules, the company deploys what it calls its APEX platform: proprietary metagenomic datasets paired with AI models that predict which phage-derived proteins will work best against specific bacterial targets. The pipeline extends beyond A. baumannii to include methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus, though those programs remain preclinical.
The Money and the Mission
The AMR Action Fund brought several co-investors into the round: Inveready, making its first commitment to Telum, alongside returning backers Invivo Capital, CDTI (through SICC Innvierte), Clave Capital, and Sodena. Telum had previously secured €4.1 million in seed funding back in mid-2020, led by Invivo Capital, with an additional €216,000 CDTI co-investment documented in March 2026.
The AMR fund itself, launched in 2020 with roughly $1 billion in committed capital, has made bringing two to four new antibiotics to patients by decade's end its stated goal. Its portfolio already includes BioVersys, which received FDA clearance to start a Phase 3 trial for—notably—the same A. baumannii target Telum is pursuing. Whether that signals confidence in the market or simply reflects how few good targets remain is an open question.
Laura Rodríguez, a partner at Invivo Capital and a Telum board member, characterized the financing as validation of the company's scientific approach. That may be true, though validation in venture capital and validation in the clinic are different beasts entirely.
The Founder's Pivot
Telum's CEO, Subhendu Basu, joined the company in early 2024 after a stint as president and COO at Adaptive Phage Therapeutics, bringing operational experience from the phage therapy world. He succeeded the founding team—Roberto Díez, now COO, and Rubén Díez, CFO—who launched the venture in Navarra in 2019. The company maintains a split presence between its Spanish base and a New York office, straddling European research infrastructure and U.S. regulatory pathways.
"This milestone funding round enables us to complete Phase 1 clinical studies for our lead program," Basu said. The company has not disclosed a specific timeline for submitting an Investigational New Drug application, though the Series A capital should fund first-in-human safety work and translational data that will determine whether the engineered enzymes perform in people as well as they do in the lab.
Beyond the lead program, Telum plans to advance candidates against other Gram-negative pathogens—Enterobacteriaceae, Pseudomonas aeruginosa—as well as Gram-positive targets. It's an ambitious pipeline for an early-stage company, perhaps more ambitious than the capital raised might suggest.
The Unsolved Economics
What makes antibiotic development particularly vexing is that scientific progress doesn't solve the underlying problem. Even breakthrough drugs face commercial headwinds: hospitals deliberately limit use to slow resistance, Medicare reimbursement models penalize novel therapies, and the patient populations are often small and acutely ill. Several antibiotic developers have filed for bankruptcy shortly after winning FDA approval, their drugs languishing on formulary lists while balance sheets bled out.
Policy interventions are materializing, slowly. The UK piloted a subscription model beginning in 2022 that decouples antibiotic revenue from volume, paying for access rather than prescriptions. The U.S. Congress has repeatedly considered the PASTEUR Act, which would establish similar pull incentives—the bill was re-introduced in 2023 but has not been enacted, and whether it gains traction remains uncertain.
For now, specialized funds like AMR Action Fund function as a partial bridge, deploying capital into programs that venture investors traditionally shun. It's a necessary mechanism, but not necessarily a sufficient one. The real test will come when Telum's lead candidate—assuming it clears Phase 1 safety hurdles—needs tens of millions more for late-stage trials and commercial readiness.
In the meantime, the bacteria keep evolving. And investors, for reasons both humanitarian and strategic, keep placing bets that this time the economics might bend differently. Whether optimism or stubbornness will prove the better descriptor remains, like so much in biotech, a question for clinical data to answer.
